Cambium Bio Ltd has released a press release.
Patent granted for cancer vaccine technology
Filed with ASX ·
6ix hasn’t read this filing yet.
Later from Cambium Bio
- Positive safety of first cohort in Progenza stem cell trial
- Appendix 4D and Half Yearly Report
- Response to 7.30 media commentary
- Enrolment complete and positive safety in Progenza trial
- ARC grant to progress stem cell research for chronic pain
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio